Your browser does not support JavaScript! AMOXICILLIN TABLET, FILM COATED AMOXICILLIN POWDER, FOR SUSPENSION [DR REDDYS LABORATORIES INC]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

AMOXICILLIN tablet, film coated
AMOXICILLIN powder, for suspension
[Dr Reddys Laboratories Inc]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL New Drug Application
Drug Label Sections

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use amoxicillin safely and effectively. See full prescribing information for amoxicillin.
 
Amoxicillin Capsules, Tablets, and Powder for Oral Suspension
Initial U.S. Approval: 1974

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

INDICATIONS AND USAGE

Amoxicillin is a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms.

  • Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract. (1.1 - 1.5)
  • In combination for treatment of H. pylori infection and duodenal ulcer disease. (1.6, 1.7)

DOSAGE AND ADMINISTRATION

  • In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Refer to full prescribing information for specific dosing regimens. (2.1, 2.2 , 2.3)
  • Treatment of gonorrhea is 3 grams as a single oral dose. (2.1)
  • The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. (2.2)
  • Dosing for H. pylori Infection: Triple therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days. (2.3)
  • Reduce the dose in patients with severe renal impairment (GFR < 30 mL/min). (2.4)

DOSAGE FORMS AND STRENGTHS

  • Capsules: 250 mg, 500 mg (3)
  • Tablets: 500 mg, 875 mg (3)
  • Powder for Oral Suspension: 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL (3)

CONTRAINDICATIONS

  • History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other beta-lactams (e.g., penicillins or cephalosporins) (4)

WARNINGS AND PRECAUTIONS

  • Anaphylactic reactions: Serious and occasionally fatal anaphylactic reactions have been reported in patients on penicillin therapy. Serious anaphylactic reactions require immediate emergency treatment with supportive measures. (5.1)
  • Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs. (5.2)

ADVERSE REACTIONS

The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea. (6.1)


To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Probenicid decreases renal tubular secretion of amoxicillin which may result in increased blood levels of amoxicillin. (7.1)
  • Concomitant use of amoxicillin and oral anticoagulants may increase the prolongation of prothrombin time. (7.2)
  • Coadministration with allopurinol increases the risk of rash. (7.3)
  • Amoxicillin may reduce the efficacy of oral contraceptives. (7.4)

USE IN SPECIFIC POPULATIONS

  • Pediatric: Modify dose in patients 12 weeks or younger (≤ 3 months). (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2012

Back to Highlights and Tabs

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.1 Infections of the ear, nose, and throat

1.2 Infections of the genitourinary tract

1.3 Infections of the skin and skin structure

1.4 Infections of the lower respiratory tract

1.5 Gonorrhea, acute uncomplicated (ano-genital and urethral infections in males and females)

1.6 Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole

1.7 Dual therapy for H. pylori with lansoprazole

2 DOSAGE AND ADMINISTRATION

2.1 Dosing for Adult and Pediatric Patients > 3 Months of Age

2.2 Dosing in Neonates and Infants Aged ≤ 12 Weeks (≤ 3 Months)

2.3 Dosing for H. pylori Infection

2.4 Dosing in Renal Impairment

2.5 Directions for Mixing Oral Suspension

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylactic Reactions

5.2 Clostridium difficile Associated Diarrhea

5.3 Potential for Microbial Overgrowth or Bacterial Resistance

5.4 Use in Patients With Mononucleosis

5.5 Phenylketonurics

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing or Other Experience

7 DRUG INTERACTIONS

7.1 Probenecid

7.2 Oral Anticoagulants

7.3 Allopurinol

7.4 Oral Contraceptives

7.5 Other Antibacterials

7.6 Drug/Laboratory Interactions

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Labor and Delivery

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Dosing in Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

12.4 Microbiology

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

17.1 Information for Patients

*
Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.


Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of the designated bacteria in the conditions listed below:

1.1 Infections of the ear, nose, and throat

- due to Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae.

1.2 Infections of the genitourinary tract

- due to Escherichia coli, Proteus mirabilis, or Enterococcus faecalis.

1.3 Infections of the skin and skin structure

- due to Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli.

1.4 Infections of the lower respiratory tract

- due to Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

1.5 Gonorrhea, acute uncomplicated (ano-genital and urethral infections in males and females)

- due to Neisseria gonorrhoeae .

Because of high rates of amoxicillin resistance, amoxicillin is not recommended for empiric treatment of gonorrhea. Amoxicillin use should be limited to situations where N. gonorrhoeae isolates are known to be susceptible to amoxicillin.

1.6 Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole

Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

1.7 Dual therapy for H. pylori with lansoprazole

Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

2 DOSAGE AND ADMINISTRATION

2.1 Dosing for Adult and Pediatric Patients > 3 Months of Age

Except for gonorrhea, treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days’ treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever. In some infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.

Table 1. Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age
InfectionSeverityaUsual Adult DoseUsual Dose for Children > 3 Monthsb
Ear/Nose/Throat
Skin/Skin Structure
Genitourinary Tract
Mild/Moderate500 mg every 12 hours or
250 mg every 8 hours
25 mg/kg/day in divided doses
every 12 hours
or
20 mg/kg/day in divided doses
every 8 hours
Severe875 mg every 12 hours or
500 mg every 8 hours
45 mg/kg/day in divided doses
every 12 hours
or
40 mg/kg/day in divided doses
every 8 hours
Lower Respiratory TractMild/Moderate or Severe875 mg every 12 hours or
500 mg every 8 hours
45 mg/kg/day in divided doses
every 12 hours
or
40 mg/kg/day in divided doses
every 8 hours
Gonorrhea
Acute, uncomplicated ano-genital and urethral infections in males and females
3 grams as single oral dosePrepubertal children:
50 mg/kg amoxicillin, combined with
25 mg/kg probenecid as a single dose.
Note: since probenecid is contraindicated in children under 2 years, do not use this regimen in children under 2 years of age.

a Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections.
b The children’s dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations.

2.2 Dosing in Neonates and Infants Aged ≤ 12 Weeks (≤ 3 Months)

Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days’ treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever. Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin is 30 mg/kg/day divided every 12 hours. There are currently no dosing recommendations for pediatric patients with impaired renal function.

2.3 Dosing for H. pylori Infection

Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days.


Dual therapy: The recommended adult oral dose is 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.


Please refer to clarithromycin and lansoprazole full prescribing information.

2.4 Dosing in Renal Impairment

  • Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe.
  • Severely impaired patients with a glomerular filtration rate of < 30 mL/min. should not receive a 875-mg dose.
  • Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection.
  • Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.
  • Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

2.5 Directions for Mixing Oral Suspension

Tap bottle until all powder flows freely. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder. Add remainder of the water and again shake vigorously.


Table 2. Amount of Water for Mixing Oral Suspension
StrengthBottle SizeAmount of Water
Required for Reconstitution
Oral Suspension 125 mg/5 mL80 mL62 mL
100 mL78 mL
150 mL116 mL
Oral Suspension 200 mg/5 mL50 mL39 mL
75 mL57 mL
100 mL76 mL
Oral Suspension 250 mg/5 mL80 mL59 mL
100 mL74 mL
150 mL111 mL
Oral Suspension 400 mg/5 mL50 mL36 mL
75 mL54 mL
100 mL71 mL

After reconstitution, the required amount of suspension should be placed directly on the child’s tongue for swallowing. Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately.


NOTE: SHAKE ORAL SUSPENSION WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration is preferable, but not required.

3 DOSAGE FORMS AND STRENGTHS

Capsules: 250 mg, 500 mg. Each capsule of amoxicillin, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500-mg capsule are imprinted with AMOXIL and 500.


Tablets: 500 mg, 875 mg. Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively. The 875-mg tablet is scored on the reverse side.


Powder for Oral Suspension: 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL. Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 mL of reconstituted bubble-gum-flavored suspension contains 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate.

4 CONTRAINDICATIONS

Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other β-lactam antibiotics (e.g., penicillins and cephalosporins).

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylactic Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and appropriate therapy instituted. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.

5.2 Clostridium difficile Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.3 Potential for Microbial Overgrowth or Bacterial Resistance

The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. If superinfections occur, amoxicillin should be discontinued and appropriate therapy instituted.

Prescribing amoxicillin either in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient, and increases the risk of the development of drug-resistant bacteria.

5.4 Use in Patients With Mononucleosis

A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Thus, amoxicillin should not be administered to patients with mononucleosis.

5.5 Phenylketonurics

Amoxicillin chewable tablets contain aspartame which contains phenylalanine. Each 200 mg chewable tablet contains 1.82 mg phenylalanine; each 400 mg chewable tablet contains 3.64 mg phenylalanine. The oral suspensions of amoxicillin do not contain phenylalanine and can be used by phenylketonurics.

6 ADVERSE REACTIONS

The following are discussed in more detail in other sections of the labeling:

  • Anaphylactic reactions [see Warnings and Precautions (5.1)]
  • CDAD [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.


The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea.


Triple therapy: The most frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/ lansoprazole) were diarrhea (7%), headache (6%), and taste perversion (5%).

Dual therapy: The most frequently reported adverse events for patients who received double therapy amoxicillin/lansoprazole were diarrhea (8%) and headache (7%). For more information on adverse reactions with clarithromycin or lansoprazole, refer to the Adverse Reactions section of their package inserts.

6.2 Postmarketing or Other Experience

In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of penicillins. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to amoxicillin.


  • Infections and Infestations: Mucocutaneous candidiasis.
  • Gastrointestinal: Black hairy tongue, and hemorrhagic/pseudomembranous colitis.
    Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see Warnings and Precautions (5.2)].
  • Hypersensitivity Reactions: Anaphylaxis [see Warnings and Precautions (5.1)]. Serum sickness–like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria have been reported.
  • Liver: A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.
  • Renal: Crystalluria has been reported [see Overdosage (10)].
  • Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.
  • Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported.
  • Miscellaneous: Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

7 DRUG INTERACTIONS

7.1 Probenecid

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.

7.2 Oral Anticoagulants

Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

7.3 Allopurinol

The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

7.4 Oral Contraceptives

Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

7.5 Other Antibacterials

Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. This has been demonstrated in vitro; however, the clinical significance of this interaction is not well documented.

7.6 Drug/Laboratory Interactions

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST®, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX®) be used.


Following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (3 and 6 times the 3 g human dose, based on body surface area). There was no evidence of harm to the fetus due to amoxicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, amoxicillin should be used during pregnancy only if clearly needed.

8.2 Labor and Delivery

Oral ampicillin is poorly absorbed during labor. It is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.

8.3 Nursing Mothers

Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.

8.4 Pediatric Use

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (≤ 3 months). [See Dosage and Administration (2.2).]

8.5 Geriatric Use

An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. These analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.


This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6 Dosing in Renal Impairment

Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR < 30 mL/min). See Dosing in Renal Impairment (2.4) for specific recommendations in patients with renal impairment.

10 OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms. Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin1.


Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.


Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.

11 DESCRIPTION

Formulations of amoxicillin contain amoxicillin, a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many Gram-positive and Gram-negative microorganisms. Chemically, it is (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid trihydrate. It may be represented structurally as:

.

The amoxicillin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.45.


Capsules: Each capsule of amoxicillin, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500-mg capsule are imprinted with AMOXIL and 500. Inactive ingredients: D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, magnesium stearate, and titanium dioxide.


Tablets: Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively. The 875-mg tablet is scored on the reverse side. Inactive ingredients: Colloidal silicon dioxide, crospovidone, D&C Red No. 30 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.


Powder for Oral Suspension: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125-mg reconstituted suspension contains 0.11 mEq (2.51 mg) of sodium. Each 5 mL of the 200-mg reconstituted suspension contains 0.15 mEq (3.39 mg) of sodium. Each 5 mL of the 250 mg reconstituted suspension contains 0.15 mEq (3.36 mg) of sodium; each 5 mL of the 400 mg reconstituted suspension contains 0.19 mEq (4.33 mg) of sodium. Inactive ingredients: FD&C Red No. 3, flavorings, silica gel, sodium benzoate, sodium citrate, sucrose, and xanthan gum.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Amoxicillin is an antibacterial drug. [see Microbiology (12.4)].

12.3 Pharmacokinetics

Absorption: Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of amoxicillin from the tablets and suspension of amoxicillin has been partially investigated; 400-mg and 875-mg formulations have been studied only when administered at the start of a light meal.


Orally administered doses of 250-mg and 500-mg amoxicillin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5 mcg/mL to 5.0 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively.


Mean amoxicillin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of amoxicillin with 875 mg of AUGMENTIN® (amoxicillin/clavulanate potassium) showed that the 875-mg tablet of amoxicillin produces an AUC0-∞ of 35.4 ± 8.1 mcg∙hr/mL and a Cmax of 13.8 ± 4.1 mcg/mL. Dosing was at the start of a light meal following an overnight fast.


Orally administered doses of amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3.0 mcg/mL and 3.5 mcg/mL to 5.0 mcg/mL, respectively.


Oral administration of single doses of 400-mg chewable tablets and 400 mg/5 mL suspension of amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data:

Table 3. Mean Pharmacokinetic Parameters of Amoxicillin (400 mg chewable tablets and 400 mg/5 mL suspension) in Healthy Adults
Dose*AUC0-∞ (mcg∙hr/mL)Cmax (mcg/mL)
AmoxicillinAmoxicillin (±S.D.)Amoxicillin (±S.D.)
400 mg (5 mL of suspension)17.1 (3.1)5.92 (1.62)
400 mg (1 chewable tablet)17.9 (2.4)5.18 (1.64)

*Administered at the start of a light meal.
Mean values of 24 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.


Distribution: Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. In blood serum, amoxicillin is approximately 20% protein-bound. Following a 1-gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid.

Metabolism and Excretion: The half-life of amoxicillin is 61.3 minutes. Approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours. Detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. Since most of the amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid [see DRUG INTERACTIONS (7.1)].

12.4 Microbiology

Mechanism of Action

Amoxicillin is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication. It acts through the inhibition of cell wall biosynthesis that leads to the death of the bacteria.


Method of Resistance

Resistance to amoxicillin is mediated primarily through enzymes called beta-lactamases that cleave the beta-lactam ring of amoxicillin, rendering it inactive.


Amoxicillin has been shown to be active against most isolates of the bacteria listed below, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section (1).


Gram-Positive BacteriaGram-Negative Bacteria
Enterococcus faecalisEscherichia coli
Staphylococcus spp.Haemophilus influenzae
Streptococcus pneumoniaeNeisseria gonorrhoeae
Alpha and β-hemolytic streptococci Proteus mirabilis
Helicobacter pylori

Susceptibility Test Methods: (susceptibility to amoxicillin can be determined using ampicillin powder and a 10 mcg ampicillin disk)


When available, clinical microbiology should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antimicrobial drug product for treatment.

Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution methods (broth or agar)2,3 or equivalent with standardized inoculum concentrations and standardized concentrations of ampicillin powder. The MIC values should be interpreted according to the criteria in Table 4.

Diffusion Techniques: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure3 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10 mcg ampicillin to test the susceptibility of bacteria to ampicillin. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 mcg ampicillin disk should be interpreted according to the criteria listed in Table 4.

Table 4. Susceptibility Test Interpretive Criteria for Amoxicillin
Minimum Inhibitory Concentration (mcg/mL)Disk Diffusion (zone diameter in mm)
SusceptibleIntermediateResistantSusceptibleIntermediateResistant
Enterococcus spp.≤ 8 - ≥ 16≥ 17 - ≤ 16
Staphylococcus spp.≤ 0.25≥ 0.5≥ 29≤ 28
Streptococci, viridians group
(alpha-hemolytic streptococci)
≤ 0.250.5 to 4≥ 8 - - -
β-hemolytic streptococci≤ 0.25 - - ≥ 24 - -
Streptococcus pneumoniae (non-meningitis isolates)*≤ 24≥ 8 - - -
Enterobacteriaceae≤ 816≥ 32≥ 1714 to 16≤ 13
Haemophilus influenzae≤ 12≥ 4≥ 2219 to 21≤ 18
Neisseria gonorrhoeae** - - - - - -

*S. pneumoniae should be tested using a 1-mcg oxacillin disk. Isolates with oxacillin zone sizes of ≥ 20 mm are susceptible to amoxicillin. An amoxicillin MIC should be determined on isolates of S. pneumoniae with oxacillin zone sizes of ≤ 19 mm.
** A positive beta lactamase test indicates resistance to amoxicillin. Isolates that are resistant to penicillin by MIC testing are also expected to be resistant to amoxicillin.

A report of “Susceptible” indicates the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches concentrations that are usually achievable. A report of “Intermediate” indicates that result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. The intermediate category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. The intermediate category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches concentrations that are usually achievable and other therapy(ies) are likely to be preferred.

Quality Control:

Susceptibility techniques require use of laboratory control microorganisms to control the technical aspects of the laboratory standardized procedures.2,3,4 Standard ampicillin powder should provide the MIC values described below. For the diffusion technique using the 10-mcg ampicillin disk, the criteria are provided in Table 5.


Table 5. Acceptable Quality Control Ranges for Amoxicillin
BacteriaATCC#MIC Range (mcg/mL)Disc Diffusion Zone Range (mm)
Escherichia coli259222 to 816 to 22
Enterococcus faecalis29212 0.5 to 2
Haemophilus influenzae49247 2 to 813 to 21
Staphylococcus aureus292130.5 to 2
2592327 to 35
Streptococcus pneumoniae49619 0.06 to 0.25

# ATCC = American Type Culture Collection


Susceptibility Testing for Helicobacter pylori : Amoxicillin in vitro susceptibility testing methods for determining minimum inhibitory concentrations (MICs) and zone sizes have not been standardized, validated, or approved for testing H. pylori. Specimens for H. pylori and clarithromycin susceptibility test results should be obtained on isolates from patients who fail triple therapy. If clarithromycin resistance is found, a non-clarithromycin-containing regimen should be used.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate (AUGMENTIN). AUGMENTIN was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. AUGMENTIN was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. AUGMENTIN was negative in the mouse micronucleus test and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).

14 CLINICAL STUDIES

14.1 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Randomized, double-blind clinical studies performed in the United States in patients with H. pylori and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within 1 year) evaluated the efficacy of lansoprazole in combination with amoxicillin capsules and clarithromycin tablets as triple 14-day therapy, or in combination with amoxicillin capsules as dual 14-day therapy, for the eradication of H. pylori. Based on the results of these studies, the safety and efficacy of 2 different eradication regimens were established: Triple therapy: Amoxicillin 1 gram twice daily/clarithromycin 500 mg twice daily/lansoprazole 30 mg twice daily (see Table 6). Dual therapy: Amoxicillin 1 gram three times daily/lansoprazole 30 mg three times daily (see Table 7). All treatments were for 14 days. H. pylori eradication was defined as 2 negative tests (culture and histology) at 4 to 6 weeks following the end of treatment. Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Table 6. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Triple Therapy Regimen
StudyTriple TherapyTriple Therapy
Evaluable Analysis a
[95% Confidence Interval]
(number of patients)
Intent-to-Treat Analysisb
[95% Confidence Interval]
(number of patients)
Study 192
[80.0 - 97.7]
(n = 48)
86
[73.3 - 93.5]
(n = 55)
Study 286
[75.7 - 93.6]
(n = 66)
83
[72.0 - 90.8]
(n = 70)

a This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and H. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest®, histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.
b Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy.


Table 7. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Dual Therapy Regimen
StudyDual TherapyDual Therapy
Evaluable Analysisa
[95% Confidence Interval]
(number of patients)
Intent-to-Treat Analysisb
[95% Confidence Interval]
(number of patients)
Study 177
[62.5 - 87.2]
(n = 51)
70
[56.8 - 81.2]
(n = 60)
Study 266
[51.9 - 77.5]
(n = 58)
61
[48.5 - 72.9]
(n = 67)

a This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and H. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest®, histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.
b Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy.

15 REFERENCES

  1. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66-67.
  2. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – 8th ed. CLSI Document M7-A8, Vol. 29, No.2. CLSI, Wayne, PA, Jan. 2009.
  3. Clinical and Laboratory Standards Institute (CLSI). Performance Standard for Antimicrobial Disk Susceptibility Tests; Approved Standard – 10th ed. CLSI Document M2-A10, Vol. 29, No. 1. CLSI, Wayne, PA, 2009.
  4. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 21st Informational Supplement. Approved Standard CLSI Document M100-S21 CLSI, Wayne, PA, January 2011.

16 HOW SUPPLIED/STORAGE AND HANDLING

Capsules: Each capsule of amoxicillin, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500 mg capsule are imprinted with AMOXIL and 500.


250-mg Capsule

NDC 43598-225-01: Bottles of 100

NDC 43598-225-05: Bottles of 500


500-mg Capsule

NDC 43598-205-01: Bottles of 100

NDC 43598-205-05: Bottles of 500


Tablets: Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively. The 875-mg tablet is scored on the reverse side.


500-mg Tablet

NDC 43598-224-14: Bottles of 20

NDC 43598-224-01: Bottles of 100

NDC 43598-224-05: Bottles of 500


875-mg Tablet

NDC 43598-219-14: Bottles of 20

NDC 43598-219-01: Bottles of 100


Powder for Oral Suspension: Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 mL of reconstituted bubble-gum-flavored suspension contains 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate.


125 mg/5 mL

NDC 43598-222-80: 80-mL bottle

NDC 43598-222-52: 100-mL bottle

NDC 43598-222-53: 150-mL bottle


200 mg/5 mL

NDC 43598-223-50: 50-mL bottle

NDC 43598-223-51: 75-mL bottle

NDC 43598-223-52: 100-mL bottle


250 mg/5 mL

NDC 43598-209-80: 80-mL bottle

NDC 43598-209-52: 100-mL bottle

NDC 43598-209-53: 150-mL bottle


400 mg/5 mL

NDC 43598-207-50: 50-mL bottle

NDC 43598-207-51: 75-mL bottle

NDC 43598-207-52: 100-mL bottle


Store at or below 25°C (77°F)

  • 250 mg and 500 mg Capsules
  • 500 mg and 875 mg Tablets
  • 200 mg and 400 mg unreconstituted powder

Store Dry Powder at 20°C – 25°C (68°F – 77°F)

  • 125 mg and 250 mg unreconstituted powder

17 PATIENT COUNSELING INFORMATION

17.1 Information for Patients

  • Patients should be advised that amoxicillin may be taken every 8 hours or every 12 hours, depending on the dose prescribed.
  • Patients should be counseled that antibacterial drugs, including amoxicillin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When amoxicillin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin or other antibacterial drugs in the future.
  • Patients should be counseled that diarrhea is a common problem caused by antibiotics, and it usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
  • Patients should be aware that amoxicillin contains a penicillin class drug product that can cause allergic reactions in some individuals.

Distributed by:

Dr. Reddy's Laboratories, Inc.

Bridgewater, NJ 08807



Issued: 0612

PACKAGE LABEL - PRINCIPLE DISPLAY PANEL

NDC 43598-224-01

100 Tablets

AMOXICILLIN

Tablets

Each Tablet contains 500 mg
amoxicillin as the trihydrate

Rx Only

Use only if inner seal is intact.
Store at or below 25°C (77°F). Dispense in a tight container.
Each tablet contains 500 mg amoxicillin as the trihydrate.

Usual Dosage: 1 tablet every 12 hours.
See accompanying prescribing information.

Important: Use safety closures when dispensing this product
unless otherwise directed by physician or requested by
purchaser.

Dist. by: Dr. Reddy’s Laboratories Inc.,
Bridgewater, NJ 08807

Principle Display Panel

PACKAGE LABEL - PRINCIPLE DISPLAY PANEL

NDC 43598-219-01

100 Tablets

AMOXICILLIN

Tablets

Each Tablet contains 875 mg
amoxicillin as the trihydrate

Rx Only

Use only if inner seal is intact.
Store at or below 25°C (77°F). Dispense in a tight container.
Each tablet contains 875 mg amoxicillin as the trihydrate.

Usual Dosage: 1 tablet every 12 hours.
See accompanying prescribing information.

Important: Use safety closures when dispensing this product
unless otherwise directed by physician or requested by
purchaser.

Dist. by: Dr. Reddy’s Laboratories Inc.,
Bridgewater, NJ 08807

Principle Display Panel

PACKAGE LABEL - PRINCIPLE DISPLAY PANEL

NDC 43598-223-50

200 mg/5 mL

AMOXICILLIN

FOR ORAL SUSPENSION

When reconstituted, each 5mL contains
200 mg amoxicillin as the trihydrate

Rx Only

Directions for mixing: Tap bottle until all powder flows freely.
Add approximately 1/3 total amount of water for reconstitution
(total=39 mL); shake vigorously to wet powder. Add remaining
water; again shake vigorously. Each 5 mL (1 teaspoonful) will
contain amoxicillin trihydrate equivalent to 200 mg amoxicillin.
Dosage: Administer every 12 hours.
See accompanying prescribing information.

Keep tightly closed.
Shake well before using.
Refrigeration preferable but not required.
Discard suspension after 14 days.

Net contents: Equivalent to 2.0 grams amoxicillin.
Store dry powder at or below 25°C (77°F).

Dist. by: Dr. Reddy’s Laboratories Inc.,
Bridgewater, NJ 08807

Principle Display Panel

PACKAGE LABEL - PRINCIPLE DISPLAY PANEL

NDC 43598-207-50

400 mg/5 mL

AMOXICILLIN

FOR ORAL SUSPENSION

When reconstituted,
each 5mL contains
400 mg amoxicillin
as the trihydrate

Rx Only

Directions for mixing: Tap bottle until all powder flows freely.
Add approximately 1/3 total amount of water for reconstitution
(total=36 mL); shake vigorously to wet powder. Add remaining
water; again shake vigorously. Each 5 mL (1 teaspoonful) will
contain amoxicillin trihydrate equivalent to 400 mg amoxicillin.
Dosage: Administer every 12 hours.
See accompanying prescribing information.

Keep tightly closed.
Shake well before using.
Refrigeration preferable but not required.
Discard suspension after 14 days.

Net contents: Equivalent to 4.0 grams amoxicillin.
Store dry powder at or below 25°C (77°F).

Dist. by: Dr. Reddy’s Laboratories Inc.,
Bridgewater, NJ 08807

Principle Display Panel
AMOXICILLIN 
amoxicillin tablet, film coated
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:43598-224
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AMOXICILLIN (AMOXICILLIN ANHYDROUS) AMOXICILLIN ANHYDROUS500 mg
Inactive Ingredients
Ingredient NameStrength
SILICON DIOXIDE 
CROSPOVIDONE 
D&C RED NO. 30 
HYPROMELLOSE 2910 (5 MPA.S) 
MAGNESIUM STEARATE 
CELLULOSE, MICROCRYSTALLINE 
POLYETHYLENE GLYCOLS 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
TITANIUM DIOXIDE 
Product Characteristics
ColorPINKScoreno score
ShapeCAPSULESize17mm
FlavorImprint Code AMOXIL;500
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:43598-224-1420 in 1 BOTTLE
2NDC:43598-224-01100 in 1 BOTTLE
3NDC:43598-224-05500 in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05075407/10/1978
AMOXICILLIN 
amoxicillin tablet, film coated
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:43598-219
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AMOXICILLIN (AMOXICILLIN ANHYDROUS) AMOXICILLIN ANHYDROUS875 mg
Inactive Ingredients
Ingredient NameStrength
SILICON DIOXIDE 
CROSPOVIDONE 
D&C RED NO. 30 
HYPROMELLOSE 2910 (5 MPA.S) 
MAGNESIUM STEARATE 
CELLULOSE, MICROCRYSTALLINE 
POLYETHYLENE GLYCOLS 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
TITANIUM DIOXIDE 
Product Characteristics
ColorPINKScore2 pieces
ShapeCAPSULESize20mm
FlavorImprint Code AMOXIL;875
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:43598-219-1420 in 1 BOTTLE
2NDC:43598-219-01100 in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05075407/10/1978
AMOXICILLIN 
amoxicillin powder, for suspension
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:43598-223
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AMOXICILLIN (AMOXICILLIN ANHYDROUS) AMOXICILLIN ANHYDROUS200 mg  in 5 mL
Inactive Ingredients
Ingredient NameStrength
SODIUM0.15 meq  in 5 mL
FD&C RED NO. 3 
SILICON DIOXIDE 
SODIUM BENZOATE 
SODIUM CITRATE 
SUCROSE 
XANTHAN GUM 
Product Characteristics
Color    Score    
ShapeSize
FlavorBUBBLE GUMImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:43598-223-5050 mL in 1 BOTTLE
2NDC:43598-223-5175 mL in 1 BOTTLE
3NDC:43598-223-52100 mL in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05076004/15/1999
AMOXICILLIN 
amoxicillin powder, for suspension
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:43598-207
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AMOXICILLIN (AMOXICILLIN ANHYDROUS) AMOXICILLIN ANHYDROUS400 mg  in 5 mL
Inactive Ingredients
Ingredient NameStrength
SODIUM0.19 meq  in 5 mL
FD&C RED NO. 3 
SILICON DIOXIDE 
SODIUM BENZOATE 
SODIUM CITRATE 
SUCROSE 
XANTHAN GUM 
Product Characteristics
Color    Score    
ShapeSize
FlavorBUBBLE GUMImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:43598-207-5050 mL in 1 BOTTLE
2NDC:43598-207-5175 mL in 1 BOTTLE
3NDC:43598-207-52100 mL in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05076004/15/1999
Labeler - Dr Reddys Laboratories Inc (802315887)
Registrant - Dr. Reddy's Laboratories Inc DBA Dr. Reddy's Laboratories Tenessee, LLC (967940441)
Establishment
NameAddressID/FEIBusiness Operations
Dr. Reddy's Laboratories Inc DBA Dr. Reddy's Laboratories Tenessee, LLC 967940441manufacture(43598-224, 43598-219, 43598-223, 43598-207)
Establishment
NameAddressID/FEIBusiness Operations
Beecham Pharmaceuticals (PTE) Limited 595132580API MANUFACTURE(43598-224, 43598-219, 43598-223, 43598-207), ANALYSIS(43598-224, 43598-219, 43598-223, 43598-207)

Revised: 9/2012
 
Dr Reddys Laboratories Inc

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services